Denovo Biopharma announced the opening of its new Research & Development Center in San Diego’s Torrey Pines Science Park.

The new 7600 square ft facility now hosts Denovo’s biomarker discovery platform, US clinical team, and serves as Denovo’s US headquarters. The center will accelerate the development of Denovo’s portfolio of 3 late-stage first-in-class drugs in oncology and CNS diseases and provide adequate support for the company’s future expansion.

The company also announced  two important additions to its senior executive team. Ronald L. Shazer MD, MBA, has been appointed chief medical officer. Dr. Shazer has over a decade of extensive experience in clinical development, including managing global oncology trials. Michael F. Haller, PhD, has joined the company in the role of chief financial officer. Dr. Haller has broad experience in business development, finance and accounting, drug development, and corporate and product strategy. He was most recently chief business officer at Peloton Therapeutics, where he led the finance and accounting department in addition to business development. 

Dr. Wen Luo, Denovo’s chief executive officer commented, “The opening of the new R&D center in San Diego, one the leading genomic hubs in the world, will substantially enhance our ability to discover innovative biomarkers to personalize all drugs in our pipeline as well as recruit top talent to support our aggressive growth plans. We are also delighted to have Dr. Shazer and Dr. Haller join us, as it will add significant talent and experience to the Denovo executive team to support the company’s rapidly expanding pipeline and transform Denovo into a fully integrated late stage biotech company.”